SEC Form 4 · accession 0001179110-18-013049
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey W. Albers
Officer — CEO and President · Director
Period of report
Nov 19, 2018
Accepted (ET)
Nov 21, 2018 · 7:20 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 19, 2018 | M | 28,961 | $1.87 | A | 28,961 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.87 | Nov 19, 2018 | M | 28,961 | D | — | Jul 30, 2024 | Common Stock | 28,961 | 886,073 | D |
Explanation of responses
- F1This option was granted on July 30, 2014. This option vested as follows: (i) 12,620 shares vested in two installments at a rate of 6,310 shares on December 21, 2015 and May 21, 2016; (ii) 35,871 shares vested in three installments at a rate of 11,957 on June 21, 2016, July 21, 2016 and August 21, 2016; and (iii) 4,983 shares vested on September 21, 2016.